Abstract: Compounds of formula (I): (I) and related aspects.

Abstract: Compounds of formula (I): and related aspects.

Abstract: Compounds of formula (I) and related aspects.

Abstract: The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R?-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R? represents a (C3-C8)cycloalkyl group, abridged (C6-C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R?-L- group wherein L is a (C1-C3)alkanediyl group, and R? is an optionally substituted phenyl group, and wherein R2 represents a hydrogen atom or a (C1-C3)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates.

Abstract: Compounds of formula (I): (I) and related aspects.

Abstract: Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 (CTPS 1) inhibitors for the treatment of proliferative diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 129 to page 302; examples; biological examples 1 and 2; tables 1-17). Specific examples are e.g.: N-(4-(5-Chloropyridin-3-yl)phenyl)-2-(2-(cyclopropane-sulfonamido) pyrimidin-4-yl)butanamide (Formula P1) or 1-(2-(Cyclopropanesulfonamido)pyrimidin-4-yl)-N-(4-(6-ethoxypyrazin-2-yl)phenyl)cyclopentanecarboxamide (Formula P2).

Abstract: The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.

Abstract: The invention provides a compound of formula (I): formula (I) and the use of such compounds as cytidine triphosphate synthase 1 inhibitors, particularly in the treatment or prophylaxis of disorders associated with cell proliferation.

Abstract: Compounds of formula (I) and related aspects.

Abstract: Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of prolifera-tive diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisa-tion of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonami-N do) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).

Abstract: Compounds of formula (I), and related aspects.

Abstract: Compounds of formula (I) and related aspects.

Abstract: Compounds of formula (I): and related aspects.

Abstract: Compounds of formula (I): (I) and related aspects.

Abstract: A coolant pump includes an impeller pump wheel, a pump housing defining an outlet volute, and an outlet valve arrangement. The pump housing comprises an outlet volute housing which defines a first outlet channel comprising a valve opening. The valve opening is defined by a valve seat which defines a valve seat plane and a symmetry plane. The symmetry plane is arranged in the middle of and rectangular to the valve seat plane. The outlet valve arrangement is in the first outlet channel and comprises a valve flap which opens/closes the valve opening. The valve flap comprises a flap seat corresponding to the valve seat. The valve flap rotates around a pivot axis parallel to the symmetry plane and having an eccentricity from the symmetry plane which is between 1/20 and 1/1 of a distance of the pivot axis to the valve seat plane when the valve flap is open.

Abstract: A coolant pump includes an outlet volute comprising a pivot axis, an impeller pump, a housing, and an outlet valve arrangement. The housing comprises an outlet volute housing defining the outlet volute and comprises a volute housing wall comprising a recess, and a first outlet channel comprising a valve opening. The outlet valve arrangement is disposed in the first outlet channel and comprises a valve body which opens or closes the valve opening. The valve body comprises a circle segment body comprising a proximal surface and a maximum outside radius. The circle segment body is rotated around the pivot axis. The proximal surface is distant from the pivot axis by an offset distance which is at least ¼ of the maximum outside radius. The recess houses the circle segment body in the closed valve position. A lateral distance of the pivot axis to the volute housing wall is approximately equal to the offset distance.

Abstract: A coolant pump includes an impeller pump wheel, a pump housing defining an outlet volute, and an outlet valve arrangement. The pump housing comprises an outlet volute housing which defines a first outlet channel comprising a valve opening. The valve opening is defined by a valve seat which defines a valve seat plane and a symmetry plane. The symmetry plane is arranged in the middle of and rectangular to the valve seat plane. The outlet valve arrangement is in the first outlet channel and comprises a valve flap which opens/closes the valve opening. The valve flap comprises a flap seat corresponding to the valve seat. The valve flap rotates around a pivot axis parallel to the symmetry plane and having an eccentricity from the symmetry plane which is between 1/20 and 1/1 of a distance of the pivot axis to the valve seat plane when the valve flap is open.

Abstract: A coolant pump includes an outlet volute comprising a pivot axis, an impeller pump, a housing, and an outlet valve arrangement. The housing comprises an outlet volute housing defining the outlet volute and comprises a volute housing wall comprising a recess, and a first outlet channel comprising a valve opening. The outlet valve arrangement is disposed in the first outlet channel and comprises a valve body which opens or closes the valve opening. The valve body comprises a circle segment body comprising a proximal surface and a maximum outside radius. The circle segment body is rotated around the pivot axis. The proximal surface is distant from the pivot axis by an offset distance which is at least ¼ of the maximum outside radius. The recess houses the circle segment body in the closed valve position. A lateral distance of the pivot axis to the volute housing wall is approximately equal to the offset distance.

Abstract: The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[I,2-b]pyridazine derivatives corresponding to general formula (I): Wherein R2, R3, R7, R8, A, L and B are as defined herein. Also disclosed are the preparative methods and therapeutic use thereof.

Abstract: The invention relates to derivatives of 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine and 6-cycloamino-2-furanyl-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine with general formula (I). The invention also relates to a method for the preparation and therapeutic application thereof, in the treatment or prevention of illnesses involving casein kinase 1 epsilon and/or casein kinase 1 delta.